Dianthus Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-9.4%projected annual EPS growth
Analyst Coverage
13analysts covering
FY EPS (est.)
-$3.92next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| DNTH212 Phase 1 Healthy Volunteer Top-line Data | 31 Dec 2026 |
| Phase 2 MoMeNtum MMN Top-line Data | 31 Dec 2026 |
| CAPTIVATE Part B Top-line Guidance Update | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly1.2BTarget: Maintain sufficient capital to fund operations into 2030
CAPTIVATE Part B Patient Enrollment QuarterlyTarget: Randomize 128 patients in Part B
Quarterly Net Loss Quarterly-40.8MTarget: Manage clinical trial expenditures within projected budget
Watch Items
- Claseprubart (DNTH103) Phase 3 CAPTIVATE Trial in CIDPTrigger: Release of Part B top-line guidance by year-end 2026Action: Evaluate trial design updates, enrollment velocity, and regulatory alignment following Sanofi's riliprubart Phase 3 failure
- Claseprubart (DNTH103) Phase 2 MoMeNtum Trial in MMNTrigger: Top-line data readout in Q4 2026Action: Analyze safety, tolerability, and secondary efficacy endpoints (grip strength, time to IVIg retreatment)
- DNTH212 Phase 1 Healthy Volunteer StudyTrigger: Top-line data readout in 2H 2026Action: Review safety, tolerability, and pharmacokinetic data to prioritize clinical indications in rheumatology (SjD, SLE, DM)
Research as of 20 Jun 2026